INS and cardiovascular disorder: Whilst the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial failed to show improvements in cardiovascular disease, increased HDL levels as a result of treatment with torcetrapib reduced plasma glucose, insulin and IR by homeostatic model assessment in patients, suggesting increased HDL levels may improve IR [24].